Blueprint's application for new drug from Avapritinib is accepted by FDA

recently, Blueprintannounced(http:// that the u.SFDA(http://has accepted the company's application fornew drug(http://(NDA) for treatment of adult patients with PDGFRA exosomes with 18 mutations in the gastrointestinal interscotic tumor (GIST) or as a fourth-line therapy treatment for GISTAbout Avapritinib
Avapritinib is a highly selective powerful KIT and PDGFRA inhibitorAvapritinib is a type 1 inhibitor that targets kinase-activated conformationsIt inhibits a variety of protein kinases that carry mutations in the KIT and PDGFRA genesThe FDA has awarded avapritinib breakthrough therapy to be used for two types of indications:for the treatment of non-reprecision or metastatic GIST with PDGFR alpha D842V mutations, andone for the treatment of systemic hyperblastoma (SM), including several invasive SM subtypes, SM subtypes associated with hyperblastated leukemia (MCL) 　　Now, Blueprint Medicines has released data on clinical trial strial
s (http:// that support the application for a new drug 　　The objective remission rate (ORR) reached 86% in patients with GIST with PDGFRA exonoid 18 mutation In patients treated with GIST as a four-line therapy, THE ORR reached 22% and the median remission duration (DOR) was 10.2 months